Molecule
Epinastine is an adrenergic receptor agonist indicated for the prevention of itching associated with allergic conjunctivitis. It is available as eye drops for ophthalmic use. MedsAcross supplies Epinastine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Epinastine HCl ophthalmic solution is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. Epinastine HCl ophthalmic solution is indicated for the prevention of itching associated with allergic conjunctivitis.
Source: US FDA prescribing information
Epinastine is a topically active, direct H 1 -receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H 1 -receptor and has affinity for the histamine H 2 -receptor. Epinastine also possesses affinity for the ɑ 1, ɑ 2 -, and 5-HT 2 -receptors.
Source: US FDA prescribing information
The recommended dosage is one drop in each eye twice a day. Treatment should be continued throughout the period of exposure (i.e., until the pollen season is over or until exposure to the offending allergen is terminated), even when symptoms are absent.
Source: US FDA prescribing information
None None
Source: US FDA prescribing information
To minimize the risk of contamination, do not touch dropper tip to any surface. Keep bottle tightly closed when not in use. Epinastine HCl should not be used to treat contact lens-related irritation. Remove contact lenses prior to instillation of epinastine HCl.
Source: US FDA prescribing information
The most common ocular adverse reactions (incidence occurring in approximately 1% to 10% of epinastine HCl-treated eyes were burning sensation in the eye, folliculosis, hyperemia, and pruritus. The most common non-ocular adverse reactions, occurring in 10% epinastine HCl-treated eyes, were infection (cold symptoms and upper respiratory infections).
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Epinastine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Epinastine 0.5 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 16 October 2003 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Epinastine and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Epinastine on 16 October 2003, according to Drugs@FDA.
No listed presentation of Epinastine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.